[New diagnostic imaging approaches in multiple myeloma]
Andrea Vaccaro1, Maria Rosaria Prisco, Gianluca Gatta
1Seconda Universita di Napoli, Napoli, Italy. andreavaccaro1971@libero.it
Recenti Progressi in Medicina
|October 26, 2012
Summary
Multiple myeloma (MM) staging requires advanced imaging. Positron Emission Tomography-Fluorodeoxyglucose (PET-FDG) shows superior sensitivity for detecting disease extent, including extramedullary sites.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Context:
- Multiple myeloma (MM) is a plasma cell malignancy primarily affecting bone marrow.
- Accurate staging and management necessitate comprehensive skeletal evaluation.
- Current diagnostic imaging modalities have limitations in fully assessing MM staging, treatment, and follow-up.
Purpose:
- To evaluate the role of advanced imaging techniques in staging and managing multiple myeloma.
- To compare the sensitivity and diagnostic utility of different imaging modalities for MM.
Summary:
- Bone scintigraphy exhibits low sensitivity for MM detection.
- Technetium-99m MIBI (Tc-99m MIBI) offers insights into disease extent and activity through whole-body uptake distribution.
- Positron Emission Tomography-Fluorodeoxyglucose (PET-FDG) excels in detecting metabolically active disease, providing crucial staging and prognostic information, and is more sensitive than other methods for identifying extramedullary disease.
Impact:
- PET-FDG demonstrates higher sensitivity for localizing extramedullary disease compared to other imaging methods.
- Advanced imaging, particularly PET-FDG, enhances the accuracy of multiple myeloma staging and prognosis.
- Improved diagnostic capabilities can lead to more tailored treatment strategies and better patient outcomes.
